Despite recent advances in the treatment of medulloblastoma, patients in high-risk categories still face very poor outcomes. Evidence indicates that a subpopulation of cancer stem cells contributes to therapy resistance and tumour relapse in these patients. To prevent resistance and relapse, the development of treatment strategies tailored to target subgroup specific signalling circuits in high-risk medulloblastomas might be similarly important as targeting the cancer stem cell population. We have previously demonstrated potent antineoplastic effects for the PI3Kα selective inhibitor alpelisib in medulloblastoma. Here, we performed studies aimed to enhance the anti-medulloblastoma effects of alpelisib by simultaneous catalytic targeting of the mTOR kinase. Pharmacological mTOR inhibition potently enhanced the suppressive effects of alpelisib on cancer cell proliferation, colony formation and apoptosis and additionally blocked sphere-forming ability of medulloblastoma stem-like cancer cells in vitro. We identified the HH effector GLI1 as a target for dual PI3Kα and mTOR inhibition in SHHtype medulloblastoma and confirmed these results in HH-driven Ewing sarcoma cells. Importantly, pharmacologic mTOR inhibition greatly enhanced the inhibitory effects of alpelisib on medulloblastoma tumour growth in vivo. In summary, these findings highlight a key role for PI3K/mTOR signalling in GLI1 regulation in HH-driven cancers and suggest that combined PI3Kα/mTOR inhibition may be particularly interesting for the development of effective treatment strategies in high-risk medulloblastomas.
that target HH upstream components, thereby blocking target gene transcription 9 . However, SMO inhibitors in younger patients may result in complications due to the essential role of HH signalling during development 10, 11 . Additionally, in humans and mice, SHH-type medulloblastomas acquire resistance to SMO inhibitors 9, 12, 13 . The aforementioned challenges outline major impediments for the utility of SMO inhibitors in paediatric cancers and have encouraged the search for alternative routes to target HH downstream effectors in SHH-driven paediatric cancers.
There is extensive crosstalk between the HH pathway and other pathways that can trigger GLI transcription factor activation in the absence of canonical HH signalling 14 . This has driven development of research seeking to identify putative oncogenic targets that are not part of the canonical HH pathway but stimulate GLI transcription factor activity through non-canonical routes. One such pathway is triggered by mechanistic target of rapamycin (mTOR)/S6K1 mediated phosphorylation of GLI1, resulting in GLI1 nuclear translocation and activation of HH target genes 15 . Additionally, crosstalk between the mTOR and HH pathways cooperates to promote mRNA translation through inhibition of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and stimulation of eukaryotic translation initiation factor 4E (eIF4E) expression 16, 17 . Consistent with this, dual inhibition of the phosphatidylinositol 3-kinase (PI3K)/mTOR and HH pathways has been shown to suppress tumour growth and increase survival in a medulloblastoma flank xenograft mouse model 18 . Importantly, upregulation of components of the PI3K/AKT/mTOR pathway has been reported in SMO resistant medulloblastomas and concurrent combination of SMO antagonists with PI3K/mTOR inhibitors blocks tumour growth and prevents the development of resistance to SMO inhibitors 19, 20 . This key role for mTOR has recently been corroborated by another study, reporting that loss of mTORC1 function blocks development of SHH-driven medulloblastoma 17 . Remarkably, pharmacologic mTOR inhibition was found to reduce tumour growth and increase survival in a SMO inhibitor resistant medulloblastoma transgenic mouse model 17 . Thus, accumulating evidence indicates that blocking components of the PI3K/mTOR pathway may be a promising approach for HH driven cancers.
Activation of PI3K signalling has been reported in medulloblastoma and may contribute to development and progression of this cancer [21] [22] [23] . Importantly, strategies targeting PI3K are not limited to SHH-driven medulloblastoma because pharmacological PI3K inhibition has also shown promise in MYC-driven Group 3 mouse models of medulloblastoma 23 . Elevated PI3K/AKT activity in glioma stem cells suggests generally important roles for this pathway in brain cancer stem cells (CSCs) 24 . Additionally, the PI3K/AKT pathway is activated after irradiation in nestin-positive cells in medulloblastoma mouse models, likely to promote survival and resistance of CSCs 21 . Accordingly, inhibition of PI3K signalling was shown to inhibit proliferation and promote differentiation of stem-like cancer cells in medulloblastoma 25 . Further, our own studies have demonstrated a key role for the PI3Kα catalytic isoform (p110α) in sphere forming medulloblastoma cells and showed disruption of cancer stem cell frequencies after PIK3CA knockdown 26 . Taken together, the PI3K pathway is attracting increasing recognition as a potential target to eradicate brain CSCs regardless of medulloblastoma subtype.
While the important contributions of PI3K/AKT activation for medulloblastoma development suggest that PI3K inhibitors might show promise for the treatment of this tumour, the narrow therapeutic window of pan-PI3K inhibitors has been discouraging 27 . Efforts to determine the discrete roles of PI3K isoforms and the clinical utility of isoform-selective inhibitors for PI3Ks indicate improved target selectivity, with lower toxicity 28 . Recent advances in the development of inhibitors of the alpha catalytic isoform suggest PI3Kα may be of particular interest for therapeutic approaches 29 . However, several studies have found that selective PI3Kα inhibition results in activation of the mTOR pathway to promote survival and resistance [30] [31] [32] [33] .
Here, we sought to investigate the therapeutic effects of combined PI3Kα and mTOR inhibition in medulloblastoma and in particular the effects on the CSC population. We report evidence for a discrete role of the PI3Kα/ mTOR pathway in SHH subtype medulloblastoma. We found dual PI3Kα and mTOR inhibition strongly reduced the amount of nuclear GLI1 protein in HH-driven medulloblastoma and similar results were observed in Ewing sarcoma, another HH-driven paediatric cancer. Finally, combined PI3Kα and mTOR targeting disrupted cancer stem cell frequencies in vitro and significantly inhibited tumour growth in a flank tumour xenograft mouse model in vivo. These results suggest that selective PI3Kα targeting combined with mTOR inhibition has a therapeutic effect in medulloblastoma and potentially other HH-driven paediatric cancers.
Results
Alpelisib and OSI-027 inhibit PI3K/mTOR signalling and exhibit antineoplastic effects in medulloblastoma cells. Alpelisib is a PI3Kα-specific inhibitor with a tolerable safety profile 34 . However, several independent studies reported activation of resistance pathways, including mTORC1 signalling, that confer resistance to alpelisib in several solid tumours [30] [31] [32] [33] . Thus, we sought to investigate the effects of simultaneous inhibition of PI3Kα and mTOR in DAOY and D556 medulloblastoma cells. We chose two cell lines that represent the highest risk category with very poor prognosis; DAOY representing the SHH, TP53 mutated and D556 representing the Group 3 MYC amplified category 8, 35, 36 . Combined treatment with alpelisib and the catalytic mTOR inhibitor OSI-027 decreased phosphorylation of AKT (Ser 473 ), S6K1 (Thr 389 ), and 4E-BP1 (Thr 37/46 ) ( Fig. 1A,B ). These results suggest that combined PI3Kα and mTOR inhibition potently blocks signalling of the PI3K-AKT-mTOR axis in medulloblastoma. This prompted us to study the biological effects of combined PI3Kα and mTOR inhibition. Initial experiments examined the dose response curves for inhibition of cell viability by alpelisib and OSI-027. In DAOY and D556 cells, combination of alpelisib with OSI-027 resulted in stronger suppression of cell viability as compared to either agent alone (Fig. 1C,D) . In DAOY cells, the half maximal inhibitory concentration (IC 50 ) decreased from 12.31 μM (alpelisib) and 1.703 μM (OSI-027) to 0.59 μM for the combination treatment (alpelisib and OSI-027) (Fig. 1C ). In D556 cells, the IC 50 decreased from 21.2 μM (alpelisib) and 5.889 μM (OSI-027) to 3.035 μM for the combination of alpelisib and OSI-027 ( Fig. 1D ). We next calculated the combination index (CI) for this drug combination. The CI defines additive effects (CI = 1), synergism (CI < 1) or antagonism (CI > 1) 37 . The combination of alpelisib with OSI-027 resulted in synergistic effects in both cell lines with CI and/or OSI-027 (10 μM) for 90 minutes and subjected to immunoblotting with antibodies against phospho-4EBP1 T37/46 and phospho-S6K1 T389 . Membranes were stripped and reprobed with antibodies for 4EBP1, S6K1 and GAPDH. Lysates from the same experiment were run in parallel and subjected to immunoblotting with antibodies against phospho-AKT S473 followed by stripping and reprobing with antibodies for AKT. Blots were analysed by autoradiography. Uncropped blots are presented in the supplement. (C,D) DAOY (C) or D556 (D) cells in 96-well plates (2000 cells per well) were treated with alpelisib and/or OSI-027 at increasing concentrations for 5 days and cell viability was determined using the cell proliferation reagent, WST-1. Prism GraphPad 7.0 was used to determine IC 50 values and CI values were calculated using Compusyn. Data represent means ± SEM of 3 independent experiments, each done in triplicate. (E,F) DAOY (E) or D556 (F) cells were seeded in soft agar in 96-well plates (1500 cells per well), treated with alpelisib (1 μM) and/or OSI-027 (1 μM). After 7 days, colony formation was quantified using the fluorescent CyQUANT GR Dye. Data represent means ± SEM of 5 independent experiments, each done in triplicate. Unpaired one-way ANOVA, *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001. (G,H) DAOY (G) or D556 (H) cells were treated with alpelisib (10 μM) and/or OSI-027 (2 μM). After 2 days, apoptosis was assessed by costaining cells with propidium iodide (PI) and annexin V-FITC followed by flow cytometry analysis. Annexin V positive cells were quantified to determine total apoptosis. Data represent means ± SEM of 4 (DAOY) and 5 (D556) independent experiments. Unpaired one-way ANOVA, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. values of 0.393 for DAOY and 0.636 in D556 cells, respectively. These findings are consistent with potent synergistic inhibitory effects in both cell lines, with such synergism being more potent in SHH-driven DAOY cells as compared to D556 cells that represent Group 3 medulloblastoma. In further studies, we found growth of colonies in soft agar was also potently inhibited by the combination of alpelisib and OSI-027 ( Fig. 1E,F) . Additionally, the combination of the two agents increased the rate of apoptosis substantially more than either agent alone ( Fig. 1G,H) . Together, these results suggest that catalytic mTOR inhibition strongly enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma cells.
PIK3CA expression is elevated in the SHH-subgroup and correlates with GLI1 expression in medulloblastoma.
Recently, at least four major subtypes of medulloblastoma have been described 3, 38 . We next sought to investigate whether distinct subgroups may show different dependencies on the PI3Kα signalling axis. Analysis using the Northcott dataset 39 revealed that PIK3CA was most highly expressed in SHH subtype medulloblastoma ( Fig. 2A ). PIK3CA expression was also found to positively correlate with expression of the HH effector transcription factor glioma-associated oncogene 1 (GLI1) ( Fig. 2B ). Furthermore, pathway enrichment analysis indicates that GLI1 expression is significantly associated with the "PI3K-AKT signalling pathway" in medulloblastoma ( Fig. 2C ). Together, these data indicate a correlation between PIK3CA expression and GLI1 in medulloblastoma and raise the possibility of a functional relationship between PI3Kα signalling and the GLI1 transcription factor in HH driven cancers.
Dual PI3Kα and mTOR inhibition decrease the amount of nuclear GLI1 and exhibit potent antineoplastic effects in Ewing sarcoma cells. GLI1 phosphorylation by the mTOR/S6K1 path-
way promotes GLI1 nuclear localization and transcriptional activity, providing a mechanism for smoothened (SMO)-independent GLI1 activation 15 . We examined the effects of PI3Kα and mTOR inhibition on GLI1 nuclear accumulation in SHH-driven medulloblastoma using nuclear/cytoplasmic fractionation of DAOY cells with Lamin A/C and tubulin as nuclear and cytoplasmic loading controls, respectively. Combination of alpelisib and OSI-027 resulted in a decrease of nuclear GLI1 protein amounts, which was more pronounced as compared to www.nature.com/scientificreports www.nature.com/scientificreports/ single agent treatment (Fig. 3A ). Next, we sought to investigate whether this GLI1 regulation by PI3Kα/mTOR is also evident in other HH-driven paediatric cancers. GLI1 transcription is directly induced by Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 (EWS-FLI1), which promotes carcinogenesis of Ewing sarcoma Family of Tumors (ESFT) 40 . Therefore, we employed two Ewing sarcoma cell lines (TC71 and RDES) to examine GLI1 cytoplasmic/nuclear distribution in this cancer. Importantly, in TC71 and RDES Ewing sarcoma cells, combined PI3Kα and mTOR inhibition resulted in reduced nuclear GLI1 (Fig. 3B,C) . The reduction of GLI1 protein in the nucleus after dual PI3Kα and mTOR inhibition indicates a requirement for PI3Kα and mTOR activities to sustain nuclear GLI1 in HH-driven cancers. HH-driven cancers strongly depend on nuclear GLIs for transcriptional activation of GLI target genes to promote proliferation and tumorigenesis 41 . Therefore, reduced nuclear GLI protein may contribute to suppression of tumour cell proliferation. In line with this, TC71 and RDES Ewing sarcoma cells exhibited high sensitivity to alpelisib and OSI-027 with IC 50 values in the nanomolar range for the alpelisib/OSI-027 combination (TC71: 74 nM; RDES: 189 nM) ( Fig. 3D,E) . Additionally, dual PI3Kα and mTOR inhibition significantly reduced anchorage-independent growth of TC71 and RDES cells in soft agar as compared to either drug alone (Fig. 3F,G) . These data support a role for PI3Kα and mTOR activities in maintaining nuclear GLI1 protein and inhibition of PI3Kα and mTOR disrupts the accumulation of GLI1 in the nucleus which may, at least in part, contribute to greatly reduced cell viability and colony formation in HH-driven paediatric cancers.
Inhibition of PI3Kα or PIK3CA knockdown reduces sphere formation and disrupts medulloblastoma stem cell frequencies when combined with pharmacologic mTOR inhibition. Next
we sought to test the effects of combined PI3Kα and mTOR inhibition on stem-like cancer cells grown in 3-D. Ewing sarcoma spheroids may not represent a reliable system to study stem-like cancer cell biology 42 . By contrast, we and others have shown that medulloblastoma cells grown under cancer stem cell conditions form 3-D neurospheres that adopt cancer stem cell characteristics 26, [43] [44] [45] . We have also demonstrated a key role for the alpha catalytic PI3K isoform in medulloblastoma sphere-forming cells 26 . Therefore, we used medulloblastoma neurospheres grown in 3-D to study sphere-forming ability of stem-like cancer cells. Neurosphere growth was potently inhibited by alpelisib and OSI-027 and combination of both inhibitors resulted in significantly stronger blockade of neurosphere growth than either drug alone (Fig. 4A,B) . These results indicate greatly reduced sphere-forming ability of medulloblastoma neurospheres after dual PI3Kα and mTOR inhibition.
We have previously investigated distinct roles for Class I A PI3K isoforms and reported that expression of PIK3CA correlates with the expression of pluripotency/stem cell markers in medulloblastoma suggesting an important role for PI3Kα in the biology of medulloblastoma CSCs 26 . In line with this, we demonstrated an essential role for PIK3CA but not PIK3CB or PIK3CD in maintaining self-renewal capacities of stem-like cancer cells as judged by disruption of stem cell frequencies after knockdown of Class I A catalytic isoforms in extreme limiting dilution analysis (ELDA) 26 . However, evidence from breast cancer suggests a role for mTORC1 in resistance to selective PI3Kα inhibition and thus a requirement for mTORC1 blockade to enhance efficacy of PI3Kα inhibition 30, 32 . Also, our previous work has demonstrated that the effects of PIK3CA knockdown or pharmacological PI3Kα inhibition can be enhanced by concomitant inhibition of pro-survival pathways in medulloblastoma 26 . Therefore, we used RNA interference (RNAi) to determine a possible role for mTOR activity in maintaining CSC frequencies after PIK3CA knockdown. PIK3CA knockdown strongly reduced the proportion of cells with self-renewal capacity in both DAOY ( Fig. 4C ) and D556 (Fig. 4D ) cells. Importantly, the combination of OSI-027 with PIK3CA knockdown significantly reduced stem cell frequencies over either PIK3CA knockdown or OSI-027 single agent alone. Specifically, stem cell frequencies in DAOY dropped from 1 in 394.2 cells for PIK3CA knockdown or 1 in 544 for OSI-027 to 1 in 1526.8 for the combination PIK3CA knockdown and OSI-027 ( Fig. 4E) . Similar results were observed for D556 where stem cell frequencies decreased from 1 in 221.1 for PIK3CA knockdown or 1 in 123.4 for OSI-027 to 1 in 1366.4 for the combination (Fig. 4F ). Chi-square analysis revealed these changes in stem cell frequencies were highly significant ( Fig. 4G,H left panels) . Knockdown of p110α protein was monitored by western blot analysis (Fig. 4G,H right panels) . These results indicate that pharmacologic mTOR inhibition enhances the disruptive effects of PIK3CA knockdown on stem cell frequencies and suggest dual inhibition of PI3Kα and mTOR is required to efficiently block self-renewal capabilities of medulloblastoma CSCs.
Dual PI3Kα and mTOR inhibition reduces tumour growth in a medulloblastoma flank tumour xenograft.
Given the potent antineoplastic effects of alpelisib and OSI-027 in vitro, we next sought to investigate the effects of dual PI3Kα and mTOR inhibition in vivo. As DAOY cells are representatives of high-risk SHH-driven medulloblastoma 35 , we used a DAOY medulloblastoma flank tumour xenograft mouse model to study the antitumor activity of combined PI3Kα and mTOR inhibition. DAOY cells in matrigel were injected subcutaneously in the flanks of nude mice and when tumours were palpable, mice were treated with vehicle controls (VC), alpelisib, OSI-027 or the alpelisib/OSI-027 combination (5 days treatment, 2 days rest followed by another 4 days treatment). While each drug moderately reduced the rate of tumour growth relative to vehicle control treated mice, the alpelisib/OSI-027 combination significantly reduced tumour growth as compared to either drug alone (Fig. 5A) . The absence of obvious changes in body weight suggests that the combination of alpelisib with OSI-027 at these concentrations was well tolerated while still reducing tumour growth (Fig. 5B) .
(F,G) TC71 (F) or RDES (G) Ewing Sarcoma cells were seeded in soft agar in 96-well plates (5000 cells per well), treated with alpelisib (0.3 μM) and/or OSI-027 (0.3 μM). After 10 days, colony formation was quantified using the fluorescent CyQUANT GR Dye. Data represent means ± SEM of 3 independent experiments, each done in triplicate. Unpaired one-way ANOVA, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
Discussion
Current treatments have produced promising results for many patients diagnosed with medulloblastoma, but not for patients with high-risk tumours. Due to the poor prognosis of some SHH medulloblastomas, the 2016 WHO consensus conference has reclassified subgroups into: WNT, SHH and TP53 wild-type, SHH and TP53 mutant, and non-WNT/non-SHH (encompassing Group 3 and Group 4 within this subgroup) 7 . Together with Group 3, metastatic and Group 3 MYC amplified medulloblastoma, SHH, TP53 mutant medulloblastoma has been identified as the highest risk category with very poor prognosis, as evident from 5-year overall survival rates of only 41% 8, 36 . This very poor prognosis resulted in listing these patients with SHH, TP53 mutations as their own category by the WHO 7, 46 .
In the current study, we investigated the effects of combined PI3Kα and mTOR inhibition in two of the highest risk category medulloblastoma cells, with DAOY cells representing the SHH, TP53 mutant and D556 cells representing the Group 3 MYC amplified categories 35 . The p110α isoform is highly expressed or activated among medulloblastoma patient samples 47 , and several investigations have been reporting promising results for targeting PI3K signalling in the SHH-driven subgroup [17] [18] [19] and the MYC-driven Group 3 23, 48 . We utilized the PI3Kα selective inhibitor alpelisib, because the alpha catalytic isoform p110α exerts important roles in medulloblastoma 47, 49 and is the only Class I A PI3K essential for sphere-forming ability and stem cell frequencies in medulloblastoma stem-like cancer cells 26 . Isoform-selective PI3Kα inhibitors are now extensively exploited because of higher efficacy and lower toxicity as compared to pan-PI3K inhibitors 29 . Alpelisib is one such PI3Kα selective inhibitor with encouraging results in early phase clinical trials and has a suitable safety profile 34 . However, it has been reported that tumours develop resistance to alpelisib by activation of the mTOR pathway 30, 31, 33 . Therefore, we reasoned that alpelisib should be tested in combination with pharmacological mTOR inhibitors. We found that the combination of alpelisib with the catalytic mTOR inhibitor OSI-027 efficiently blocked signalling of the PI3K/AKT/mTOR pathway, exhibited potent antineoplastic effects, induced apoptosis and inhibited sphere formation. Additionally, knockdown of PIK3CA (encoding p110α) in combination with OSI-027 disrupted stem cell frequencies. Thus, dual PI3Kα and mTOR inhibition is a comprehensive strategy that includes targeting the CSC population and therefore shows promise for treatment of high-risk category medulloblastoma in different subgroups.
Interestingly, PIK3CA expression is highest in the SHH subgroup (see Fig. 2A ). Also, expression of the HH effector GLI1 correlates with PIK3CA expression and is associated with enrichment of the PI3K-AKT pathway (see Fig. 2B,C) . GLI transcription factors are the main downstream effectors of the canonical and the non-canonical HH cascade and are involved in the stimulation of multiple oncogenic signalling pathways 41 . We found nuclear GLI1 protein amounts were reduced in DAOY cells after combined PI3Kα and mTOR inhibition, indicating a role for PI3K/mTOR signalling in the regulation of GLI1 in the SHH subgroup. This observation prompted us to further investigate the mechanistic role of PI3Kα and mTOR in additional HH-driven paediatric cancers.
Survival and tumorigenesis of Ewing sarcoma is dependent on EWS-FLI1, a constitutively active chimeric transcription factor 50 . The HH effector GLI1 is a direct transcriptional target of EWS-FLI1 and exerts key roles in Ewing sarcoma tumorigenesis 40 . We chose Ewing sarcoma because this tumour type was shown to directly dependent on GLI1 and knockdown or inhibition of GLI1 exerts antineoplastic effects in this cancer 40, 51, 52 . We found that combination of alpelisib and OSI-027 resulted in substantial reduction of GLI1 nuclear protein. This suggests that continuous activity of the PI3K/mTOR axis is required to maintain high levels of GLI1 in the nucleus and inhibition of this pathway results in a reduction of nuclear GLI1 protein amounts. This is in agreement with the finding that the mTOR downstream effector S6K1 directly phosphorylates GLI1, resulting in nuclear translocation and activation of GLI1 independent of SMO 15 . Significantly, Ewing sarcoma cells were highly sensitive www.nature.com/scientificreports www.nature.com/scientificreports/ to PI3Kα and mTOR inhibition with IC 50 values in the nanomolar range for the combination of both inhibitors. These findings suggest that PI3K/mTOR signalling contributes to tumorigenesis in HH-driven paediatric cancers through non-canonical activation of HH downstream effectors independently of canonical HH signalling through SMO. They further raise the possibility of targeting the PI3K/mTOR axis as a promising therapeutic approach in HH driven cancers that are resistant to SMO inhibitors. This notion is supported by the finding of the TC71 Ewing Sarcoma cell line showing resistance to the SMO inhibitor cyclopamine 40 , while being highly susceptible to combined PI3Kα and mTOR inhibition in the nanomolar range. This is of particular interest because medulloblastomas resistant to SMO inhibitors have been shown to activate the PI3K/AKT/mTOR pathway 19, 20 . Thus it is possible that increased PI3K and mTOR activities contribute to SMO inhibitor resistance by sustaining high nuclear GLI1 levels. In line with this, PI3K/mTOR inhibitors interfere with the development of resistance to SMO inhibitors in medulloblastoma 19 . Hence, PI3Kα/mTOR targeting might be a promising strategy for HH-driven cancers that are resistant to SMO inhibitors.
Here, we demonstrate potent anti-tumor effects after dual PI3K/mTOR inhibition that may be mediated, at least in part, by disrupting nuclear GLI1. Still, given the complexity of the crosstalk between the HH and PI3K/ mTOR pathways, it is possible that inhibitory effects on additional pathway components contribute to these antineoplastic effects. Further mechanistic studies will be required to elucidate to which extent the disruption of stem cell frequencies, the inhibition of mTOR mediated mRNA translation and the inhibitory effects on nuclear GLI1 protein contribute to this phenotype. Nevertheless, our findings suggest that HH-driven paediatric cancers can be targeted by inhibition of the PI3K/mTOR pathway and raise the interesting possibility that this strategy might be exceptionally efficient in cancers that are highly dependent on non-canonical HH signalling and that are resistant to SMO inhibitors.
Materials and Methods
Cell culture and reagents. DAOY and D556 medulloblastoma cells were grown in DMEM supplemented with 10% FBS and gentamycin (0.1 mg/ml). TC71 and RDES Ewing sarcoma cells were grown in RPMI-1640 supplemented with 10% FBS and penicillin (100 U/ml)/streptomycin (100 ng/ml). 3-D stem-like cancer cell cultures were described in detail previously 26, 53, 54 . The identity of established cell lines was authenticated by short-tandem repeat (STR) analysis (Genetica DNA Laboratories) in December 2017 (medulloblastoma lines) and August 2016 (Ewing sarcoma lines). All cells were grown at 37 °C in 5% CO 2 . Aleplisib (BYL-719) and OSI-027 were purchased from ChemieTek and dissolved in DMSO as vehicle for in vitro studies.
Immunoblotting and antibodies. Cells were lysed in phosphorylation lysis buffer (pH 7.9) containing 50 mM HEPES, 150 mM NaCl, 1 mM MgCl 2 , 0.5% sodium deoxycholate and supplemented with phosphatase and protease inhibitors (Roche). For cell fractionation, the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher) was used according the manufacturer's instructions. Protein concentration was quantified by Bradford assay (Bio-Rad) with the Synergy HT plate reader and Gen5 software (Biotek). Equal amounts of protein lysate were subjected to SDS-PAGE (Bio-Rad) followed by transfer to Low Fluorescent PVDF membranes (Bio-Rad). Membranes were blocked with 5% BSA or 5% milk and cut horizontally to allow for incubation with different primary antibodies overnight at 4 °C. Membranes were then incubated in secondary horseradish peroxidase (HRP)-conjugated antibody for 1 hour, and analysed using the WesternBright ECL substrate (GE Healthcare) and either autoradiography film (Denville Scientific) or the ChemiDoc MP Imaging System and Image Lab 5.0 software (Bio-Rad) as described 26 . Antibodies were removed, where indicated, using Restore PLUS Western Blot Stripping Buffer (Thermo Fisher) to allow for incubation with additional antibodies. A comprehensive list of antibodies used in this study can be found in Supplemental Table 1 . Uncropped blots are presented in the supplement.
Cell viability and apoptosis assays. Cell viability was assessed using the Cell Proliferation Reagent
WST-1 (Roche) as described previously 26 . Briefly, cells were seeded into 96-well plates at a density of 1,500 cells per well (for medulloblastoma cell lines) or 5,000 cells per well (Ewing sarcoma cell lines) with the indicated drugs. After incubation at 37 °C in 5% CO 2 for 5 days, the WST-1 reagent (10% v/v) was added and cell viability was assessed using the Synergy HT plate reader and Gen5 software (BioTek) as described 55 . Apoptosis assay was done as described before 56 .
Soft agar assays.
For investigation of anchorage-independent cell growth, soft-agar assays were performed using the CytoSelect 96-Well Cell Transformation Assay Kit (Cell Biolabs, Inc.) according to the manufacturer's instructions. In brief, medulloblastoma and Ewing sarcoma cells were seeded in soft-agar in a 96-well plate and incubated at 37 °C in 5% CO 2 with the indicated inhibitors for 7 days (medulloblastoma cell lines) or 10 days (Ewing sarcoma cell lines) before agar was solubilized and cells were lysed according to the manufacturer's instructions. Colony formation was assessed as previously described 55 . Bioinformatics and statistical analysis. For gene expression analysis, the GlioVis portal 57 was employed to obtain data of the Northcott_2012 dataset 39 . These data were subjected to analysis in GraphPad Prism 7.0 as described before 26 . Also, statistical analyses were performed using Prism Graphpad 7.0, including calculation of IC 50 values. For comparison of more than two groups one-way analysis of variance (ANOVA) was used followed by Tukey's test. For comparison of more than two groups and multiple time points, two-way ANOVA was used followed by Tukey's test. Comparison of stem cell frequencies of different groups for ELDA was done by Chi square (χ 2 ) test. CI values were calculated for the IC 50 values using Compusyn as described before 58 .
